应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
LLY 礼来
盘后交易 11-21 18:33:27 EST
749.92
-3.49
-0.46%
盘后
747.50
-2.42
-0.32%
18:33 EST
最高
753.00
最低
735.00
成交量
414.15万
今开
746.12
昨收
753.41
日振幅
2.39%
总市值
7,119亿
流通市值
7,109亿
总股本
9.49亿
成交额
30.87亿
换手率
0.44%
流通股本
9.48亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
礼来下跌1.23%，报744.11美元/股
金融界 · 11-21 22:30
礼来下跌1.23%，报744.11美元/股
分析-华尔街等待安进减肥药数据有望推动股价上涨
路透中文 · 11-21 19:00
分析-华尔街等待安进减肥药数据有望推动股价上涨
BUZZ-中国莱克纳因折价销售股票而创下 7 个月来最大跌幅
路透中文 · 11-21 12:30
BUZZ-中国莱克纳因折价销售股票而创下 7 个月来最大跌幅
《股市简讯》来凯医药一度急泻13%，此前大幅“炒高”后折价配股筹资
路透中文 · 11-21 10:57
《股市简讯》来凯医药一度急泻13%，此前大幅“炒高”后折价配股筹资
中国生物技术公司莱克纳与礼来合作开发保护肌肉的肥胖症药物
路透中文 · 11-20 23:07
中国生物技术公司莱克纳与礼来合作开发保护肌肉的肥胖症药物
专访礼来中国总裁兼总经理德赫兰：礼来在中国的长期主义战略
中国新闻网 · 11-20 22:21
专访礼来中国总裁兼总经理德赫兰：礼来在中国的长期主义战略
加快减肥药研发 来凯医药与礼来展开临床合作
经济参考网 · 11-20 20:05
加快减肥药研发 来凯医药与礼来展开临床合作
美世调查发现，减肥药在美国最大雇主中的覆盖率上升
Reuters · 11-20 19:00
美世调查发现，减肥药在美国最大雇主中的覆盖率上升
政策压力下率先反弹，“减肥药新贵”Viking能否抗衡“诺礼双雄”？
老虎资讯综合 · 11-20 18:33
政策压力下率先反弹，“减肥药新贵”Viking能否抗衡“诺礼双雄”？
BUZZ-在香港上市的莱克纳因礼来公司的交易而创下 10 个月以来的新高
Reuters · 11-20 13:57
BUZZ-在香港上市的莱克纳因礼来公司的交易而创下 10 个月以来的新高
来凯医药与礼来合作在美国开展LAE102治疗肥胖症的临床试验
金吾财讯 · 11-20 13:34
来凯医药与礼来合作在美国开展LAE102治疗肥胖症的临床试验
来凯医药与礼来签署LAE102临床合作协议
财中社 · 11-20 13:27
来凯医药与礼来签署LAE102临床合作协议
来凯医药-B(02105)与礼来签订一项临床合作协议
智通财经 · 11-20 12:17
来凯医药-B(02105)与礼来签订一项临床合作协议
背景资料-诺和诺德减肥药 Wegovy 的价格和供应情况
路透中文 · 11-19 22:02
背景资料-诺和诺德减肥药 Wegovy 的价格和供应情况
部分药品企业拒不接受价格整改要求，涉赛诺菲、礼来、恒瑞、正大天晴等
财经网 · 11-19 18:47
部分药品企业拒不接受价格整改要求，涉赛诺菲、礼来、恒瑞、正大天晴等
礼来替尔泊肽SURMOUNT-1研究公布详细结果
每日经济新闻 · 11-19 17:36
礼来替尔泊肽SURMOUNT-1研究公布详细结果
礼来(LLY.US)潜在首创口服小分子显著降低心血管事件高风险成人Lp(a)水平
智通财经 · 11-19 16:43
礼来(LLY.US)潜在首创口服小分子显著降低心血管事件高风险成人Lp(a)水平
阿斯利康、礼来亚洲基金等入股呈元科技
界面 · 11-19 15:23
阿斯利康、礼来亚洲基金等入股呈元科技
研究发现礼来药片可将遗传性胆固醇降低近 86
Reuters · 11-19
研究发现礼来药片可将遗传性胆固醇降低近 86
美股走势-Henry Schein Inc、Palantir Technologies、Uber Technologies
路透中文 · 11-19
美股走势-Henry Schein Inc、Palantir Technologies、Uber Technologies
暂无数据
公司概况
公司名称：
礼来
所属市场：
NYSE
上市日期：
--
主营业务：
礼来公司于1901年在印第安纳州注册成立，其前身是1876年由伊利·礼来上校在印第安纳州印第安纳波利斯创立的药品生产企业。公司发现，开发，制造和销售重要医药产品。公司的宗旨是将“关爱”与“发现”结合起来，为世界各地的人们创造更美好的生活。
发行价格：
--
{"stockData":{"symbol":"LLY","market":"US","secType":"STK","nameCN":"礼来","latestPrice":749.92,"timestamp":1732222800000,"preClose":753.41,"halted":0,"volume":4141476,"hourTrading":{"tag":"盘后","latestPrice":747.5,"preClose":749.92,"latestTime":"18:33 EST","volume":470605,"amount":352913136.78849995,"timestamp":1732231987090},"delay":0,"floatShares":948000000,"shares":949315694,"eps":8.121151,"marketStatus":"盘后交易","marketStatusCode":4,"change":-3.49,"latestTime":"11-21 18:33:27 EST","open":746.12,"high":752.9999,"low":735,"amount":3087464974.0812,"amplitude":0.023891,"askPrice":749,"askSize":9,"bidPrice":747.03,"bidSize":4,"shortable":3,"etf":0,"ttmEps":8.121151,"exchange":"NYSE","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1732237200000},"adr":0,"listingDate":102488400000,"adjPreClose":753.41,"adrRate":0,"dividendRate":0.006707,"preHourTrading":{"tag":"盘前","latestPrice":746.11,"preClose":753.41,"latestTime":"09:29 EST","volume":12097,"amount":9103212.6654,"timestamp":1732199394898},"postHourTrading":{"tag":"盘后","latestPrice":747.5,"preClose":749.92,"latestTime":"18:33 EST","volume":470605,"amount":352913136.78849995,"timestamp":1732231987090},"volumeRatio":0.657814,"impliedVol":0.3848,"impliedVolPercentile":0.8294},"requestUrl":"/m/hq/s/LLY/tweets","defaultTab":"tweets","newsList":[{"id":"2485492244","title":"礼来下跌1.23%，报744.11美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485492244","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485492244?lang=zh_cn&edition=full","pubTime":"2024-11-21 22:30","pubTimestamp":1732199450,"startTime":"0","endTime":"0","summary":"11月21日，礼来(LLY)开盘下跌1.23%，截至22:30，报744.11美元/股，成交2374.63万美元。财务数据显示，截至2024年09月30日，礼来收入总额315.1亿美元，同比增长27.21%；归母净利润61.8亿美元，同比增长102.58%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/11/21223045551299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["IE00BK4W5L77.USD","LU1868836914.USD","LU1280957306.USD","SG9999014914.USD","LU1712237335.SGD","LU2361044949.HKD","LU2237443978.SGD","LU1988902786.USD","LU1127390331.HKD","IE0009355771.USD","BK4585","SG9999014906.USD","LU2106854487.HKD","LU0354030438.USD","SG9999015945.SGD","LU0466842654.USD","LU2491050071.SGD","LU1023059063.AUD","LU1366192091.USD","LU0417517546.SGD","BK4534","LU1057294990.SGD","SG9999015952.SGD","SGXZ51526630.SGD","LU1974910355.USD","LU2602419157.SGD","SG9999014880.SGD","LU0198837287.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU2491049909.HKD","LU0320765059.SGD","LU2237443895.HKD","LU0256863902.USD","LU1868837136.USD","BK4533","LU0640476718.USD","LU1868836591.USD","LU0471298694.HKD","LU2360106947.USD","LU1551013342.USD","LU2264538146.SGD","LU1061106388.HKD","IE00BK4W5M84.HKD","LU2023250504.SGD","LU2237443382.USD","SGXZ81514606.USD","LLY","LU0079474960.USD","LU0820561818.USD"],"gpt_icon":0},{"id":"2485546612","title":"分析-华尔街等待安进减肥药数据有望推动股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2485546612","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485546612?lang=zh_cn&edition=full","pubTime":"2024-11-21 19:00","pubTimestamp":1732186818,"startTime":"0","endTime":"0","summary":"分析-华尔街等待安进减肥药数据有望推动股价上涨安进公司的MariTide有望比GLP-1药物减肥更快、剂量更少分析师预计 MariTide 至少能减轻 20% 的体重对副作用的担忧，包括恶心和骨密度问题Deena Beasley. 路透11月21日 - 安进公司AMGN.O的试验性减肥药MariTide即将获得的中期研究数据将揭示它与礼来LLY.N和诺和诺德NOVOb.CO销售的流行GLP-1药物相比的效果。安进公司对为期52周的第二阶段试验发表了令人鼓舞的评论，推动该公司股价在过去一年中上涨了8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nL4S3MS0UR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU1551013425.SGD","SG9999018857.SGD","LU2237443978.SGD","LU2360106947.USD","LU0385154629.USD","LU0417517546.SGD","LU0256863811.USD","SG9999001176.SGD","LU1868836591.USD","LU1983299246.USD","LU2237443549.SGD","IE00B4R5TH58.HKD","LU0238689110.USD","LU2242646821.SGD","LU0079474960.USD","LU2491050071.SGD","LU0466842654.USD","LU1868837300.USD","LU0198837287.USD","IE00BK4W5M84.HKD","LU0203202063.USD","LU1814569148.SGD","LU0882574139.USD","LU1551013342.USD","LLY","LU0096364046.USD","LU2491050154.USD","LU0354030511.USD","BK4599","IE00BJJMRZ35.SGD","LU0203201768.USD","LU0114720955.EUR","LU0823416689.USD","LU0006306889.USD","IE00B1BXHZ80.USD","SG9999014914.USD","LU2089984988.USD","LU1868837136.USD","LU2242652126.USD","AMGN","LU0889565916.HKD","LU1917777945.USD","SG9999018865.SGD","LU2112291526.USD","LU1267930730.SGD","LU0106261372.USD","LU1023059063.AUD","LU0868494617.USD","BK4585"],"gpt_icon":1},{"id":"2485487550","title":"BUZZ-中国莱克纳因折价销售股票而创下 7 个月来最大跌幅","url":"https://stock-news.laohu8.com/highlight/detail?id=2485487550","media":"路透中文","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485487550?lang=zh_cn&edition=full","pubTime":"2024-11-21 12:30","pubTimestamp":1732163412,"startTime":"0","endTime":"0","summary":"11月21日 - ** 中国生物科技公司莱克纳2105.HK股价下跌14.9%，至13.38港元，创4月16日以来最大单日跌幅。** 莱克纳股价今年累计下跌 29.4 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nL4S3MS0BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ31699556.SGD","LU0354030438.USD","02105","LU0385154629.USD","LU0006306889.USD","LU1804176565.USD","LU0079474960.USD","BK4599","LU1280957306.USD","LU1868837300.USD","SG9999014906.USD","LU1868836591.USD","LU2112291526.USD","LU0289739699.SGD","BK4588","LU2491049909.HKD","LU0203201768.USD","LU2211815571.USD","SG9999014914.USD","IE00B2B36J28.USD","LU2237443549.SGD","LU1127390331.HKD","LLY","LU1814569148.SGD","LU0466842654.USD","LU2237443465.HKD","LU0471298777.SGD","LU0106261372.USD","SGXZ51526630.SGD","LU0061475181.USD","LU0238689110.USD","SG9999001176.USD","LU2237438978.USD","LU2237443382.USD","LU2023250504.SGD","LU2089984988.USD","SG9999015945.SGD","BK1161","LU0823416689.USD","SGXZ99366536.SGD","LU2468319806.SGD","SG9999015952.SGD","LU1917777945.USD","LU2237443622.USD","LU0094547139.USD","IE0009355771.USD","LU1093756325.SGD","LU0640476718.USD","LU0882574055.USD","BK4007"],"gpt_icon":1},{"id":"2485863344","title":"《股市简讯》来凯医药一度急泻13%，此前大幅“炒高”后折价配股筹资","url":"https://stock-news.laohu8.com/highlight/detail?id=2485863344","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485863344?lang=zh_cn&edition=full","pubTime":"2024-11-21 10:57","pubTimestamp":1732157877,"startTime":"0","endTime":"0","summary":"《股市简讯》来凯医药一度急泻13%，此前大幅“炒高”后折价配股筹资* 专注于肿瘤、代谢疾病及肝纤维化治疗的生物医药科技公司--来凯医药2105.HK周四早盘一度急泻13%，低探13.68港元。* 该公司稍早公布，透过中信证券配售1,763.6万股新股筹约2.4亿港元，以加速研发LAE102及其他针对Act RII受体的药物资产。配售价每股13.36港元，较周三收市价折让15%，或较前五个交易日平均收市价溢价约13%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nL4S3MS06Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014906.USD","LU2106854487.HKD","LU1093756168.USD","SG9999015952.SGD","IE0002141913.USD","LU0417517546.SGD","LU1023059063.AUD","LU2602419157.SGD","LU0198837287.USD","LU0689472784.USD","SG9999015945.SGD","LU1804176565.USD","SG9999001176.USD","LU2237443549.SGD","LU1623119135.USD","LU2264538146.SGD","SG9999017495.SGD","LU0058720904.USD","02105","LU2237443622.USD","LU0354030438.USD","IE00BK4W5L77.USD","LU2237443978.SGD","LU0097036916.USD","BK4533","LU0640476718.USD","LU1057294990.SGD","LU0289739699.SGD","LU1868837300.USD","LU0256863811.USD","LU1712237335.SGD","LLY","BK4585","LU0106261372.USD","LU1974910355.USD","LU1267930730.SGD","BK4516","LU1064131342.USD","LU0943347566.SGD","LU1551013425.SGD","SGXZ31699556.SGD","LU1868836591.USD","LU0708995401.HKD","LU1069344957.HKD","BK4581","IE00BJLML261.HKD","LU2265009873.SGD","SG9999014898.SGD","LU1814569148.SGD","LU0109391861.USD"],"gpt_icon":1},{"id":"2484148792","title":"中国生物技术公司莱克纳与礼来合作开发保护肌肉的肥胖症药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2484148792","media":"路透中文","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484148792?lang=zh_cn&edition=full","pubTime":"2024-11-20 23:07","pubTimestamp":1732115272,"startTime":"0","endTime":"0","summary":"中国生物技术公司莱克纳与礼来合作开发保护肌肉的肥胖症药物路透11月20日 - 礼来LLY.N和香港上市公司Laekna2105.HK周三表示，将合作开发一种实验性肥胖症药物，旨在帮助患者减轻体重，同时保留肌肉。礼来公司将资助该药物的开发，并分享其资源和专业知识，但莱克纳公司将保留该药物的全球使用权，并计划在中国推进该药物的早期试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nL4T3MR17Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0238689110.USD","LU1551013425.SGD","LU2361044949.HKD","LU0198837287.USD","SG9999013999.USD","LU0096364046.USD","SG9999014906.USD","REGN","BK4588","LU1035775433.USD","LU1804176565.USD","LU1868837136.USD","LU2237438978.USD","LU0058720904.USD","LU0823416689.USD","LU0385154629.USD","LU1814569148.SGD","LU1868837300.USD","LU2602419157.SGD","SG9999014898.SGD","SG9999018865.SGD","LU1064131342.USD","LU0471298777.SGD","LLY","LU0820561909.HKD","02105","LU2264538146.SGD","LU2063271972.USD","LU2362541513.USD","LU0122379950.USD","LU1917777945.USD","IE00BFTCPJ56.SGD","LU0354030438.USD","LU1551013342.USD","SG9999014914.USD","SG9999001176.USD","LU0079474960.USD","LU0061475181.USD","LU1974910355.USD","LU0256863811.USD","GB00BDT5M118.USD","LU0109391861.USD","LU1127390331.HKD","SRRK","LU1069344957.HKD","LU0320765992.SGD","LU0006306889.USD","LU0672654240.SGD","SG9999018857.SGD","LU2237443895.HKD"],"gpt_icon":1},{"id":"2484581117","title":"专访礼来中国总裁兼总经理德赫兰：礼来在中国的长期主义战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2484581117","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484581117?lang=zh_cn&edition=full","pubTime":"2024-11-20 22:21","pubTimestamp":1732112495,"startTime":"0","endTime":"0","summary":"中新网北京11月20日电(赵方园)自1918年在上海设立首个海外办事处起，礼来便与中国结下深厚缘分。近150年来，礼来始终致力于通过科学创新改善人类健康，并不断突破科学的边界，坚持研发创新药物。在过去6年中，礼来在中国成功获批了40种新药和新适应症，并不断加大在华投资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411203245790943.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411203245790943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1988902786.USD","SG9999015986.USD","LU0114720955.EUR","SG9999015945.SGD","IE00B1BXHZ80.USD","LU2324357040.USD","SG9999014914.USD","LU2461242641.AUD","BK4581","LU0820561909.HKD","IE00B4R5TH58.HKD","BK4007","LU2360106947.USD","IE00BFTCPJ56.SGD","IE00BK4W5M84.HKD","LU0471298694.HKD","LU1868836757.USD","GB00BDT5M118.USD","LU1069344957.HKD","IE00BJT1NW94.SGD","LU0417517546.SGD","BK4534","LU1551013425.SGD","LU0109391861.USD","LU2237443549.SGD","LU1267930730.SGD","LU2089984988.USD","LU0466842654.USD","LU2237443465.HKD","IE0004445239.USD","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU2602419157.SGD","SGXZ57979304.SGD","LU0198837287.USD","SG9999018865.SGD","SG9999015978.USD","LLY","IE00BK4W5L77.USD","LU0203201768.USD","LU2237443895.HKD","LU1366192091.USD","LU0079474960.USD","LU0943347566.SGD","LU1868836591.USD","LU2264538146.SGD","LU0203202063.USD","LU1280957306.USD","LU1035775433.USD","SG9999015952.SGD"],"gpt_icon":1},{"id":"2484487197","title":"加快减肥药研发 来凯医药与礼来展开临床合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2484487197","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484487197?lang=zh_cn&edition=full","pubTime":"2024-11-20 20:05","pubTimestamp":1732104339,"startTime":"0","endTime":"0","summary":"处于产业化临界点的新一代GLP-1药物正迫使入局者与时间赛跑，以便在行业“内卷”前分到一杯羹。来凯医药（02105.HK）11月20日发布的公告显示，公司就旗下一款减肥药与礼来展开全球临床合作，礼来将负责在美国执行一项该减肥药的Ⅰ期研究并承担相关费用。业内人士分析认为，来凯医药此举意在加快减肥药研发，同时也减小公司的资金消耗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411203245710159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0820561818.USD","SG9999014880.SGD","LU1988902786.USD","02105","LU2265009873.SGD","SG9999014898.SGD","LU1057294990.SGD","LU2237438978.USD","LU0238689110.USD","LU2324357040.USD","LU2491050154.USD","LU0823416689.USD","LU0820561909.HKD","LU1983299246.USD","IE00B4R5TH58.HKD","BK4007","LU2063271972.USD","LU1069344957.HKD","LU0417517546.SGD","BK4534","LU0256863902.USD","LU0109391861.USD","LU2237443549.SGD","LU1093756325.SGD","LU1267930730.SGD","LU2089984988.USD","SG9999001176.SGD","LU0106261372.USD","LU2491049909.HKD","LU0456855351.SGD","IE0004445239.USD","LU1868836914.USD","LU2468319806.SGD","LU0672654240.SGD","SGXZ31699556.SGD","LU0198837287.USD","IE0002141913.USD","SG9999018865.SGD","LU1804176565.USD","LLY","LU1061106388.HKD","IE00BJLML261.HKD","LU0882574139.USD","LU0203202063.USD","LU1551013342.USD","LU1280957306.USD","LU0094547139.USD","LU2461242641.AUD","LU2361044949.HKD","SG9999015952.SGD"],"gpt_icon":1},{"id":"2484119668","title":"美世调查发现，减肥药在美国最大雇主中的覆盖率上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2484119668","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484119668?lang=zh_cn&edition=full","pubTime":"2024-11-20 19:00","pubTimestamp":1732100417,"startTime":"0","endTime":"0","summary":"美世还称，2024 年，64% 员工人数超过 20,000 人的美国雇主会购买减肥药物，而去年这一比例为 56%。调查发现，肥胖症药物已导致雇主今年的成本上升，并造成整体医疗福利成本的增加，从而改变了患者获得药物的方式。美世的调查问题指的是任何一类药物中的减肥药。美世的调查涵盖 2194 家美国雇主，从拥有 500 名员工到超过 20000 名员工不等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU1814569148.SGD","LU2468319806.SGD","LU1974910355.USD","LU2112291526.USD","LU0097036916.USD","SG9999015986.USD","LU1868836757.USD","LU0354030438.USD","LU2237443978.SGD","LU1868837136.USD","SG9999015945.SGD","LU2361044865.SGD","LU0456855351.SGD","SG9999018857.SGD","SG9999018865.SGD","LU2237438978.USD","SG9999014880.SGD","SG9999001176.USD","IE00B4R5TH58.HKD","SG9999013999.USD","LU0094547139.USD","LU0256863902.USD","LU0061475181.USD","LU2361045086.USD","BK4534","LU1061106388.HKD","LU1127390331.HKD","LU0198837287.USD","LU0256863811.USD","LU0320765059.SGD","LU1983299246.USD","LU2602419157.SGD","LU0471298777.SGD","LU1868836591.USD","LU2106854487.HKD","LU2361044949.HKD","LU0006306889.USD","LU2491050154.USD","LU0708995401.HKD","LU1917777945.USD","SGXZ99366536.SGD","BK4588","LU1712237335.SGD","LU2023250504.SGD","LU0466842654.USD","LU2324357040.USD","BK4585","IE0009355771.USD","LLY"],"gpt_icon":1},{"id":"1106223865","title":"政策压力下率先反弹，“减肥药新贵”Viking能否抗衡“诺礼双雄”？","url":"https://stock-news.laohu8.com/highlight/detail?id=1106223865","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106223865?lang=zh_cn&edition=full","pubTime":"2024-11-20 18:33","pubTimestamp":1732098801,"startTime":"0","endTime":"0","summary":"不过从实际情况来看，肥胖人群对减肥药物的需求持续高企，而“减肥药新贵” Viking的新型口服减肥药VK2809后来居上，甚至有力压老牌减肥药物巨头“诺礼双雄”的势头。此前，Viking还公布了VK2735注射版的最新数据。考虑到规模及品牌效应，目前主导肥胖药物领域的仍然是诺和诺德和礼来两大巨头，但“减肥药新贵”Viking的异军突起，或许将让他们未来面临严峻的竞争。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","VKTX","LLY"],"gpt_icon":0},{"id":"2484155247","title":"BUZZ-在香港上市的莱克纳因礼来公司的交易而创下 10 个月以来的新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2484155247","media":"Reuters","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484155247?lang=zh_cn&edition=full","pubTime":"2024-11-20 13:57","pubTimestamp":1732082228,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) 11月20日 - ** 在香港上市的莱克纳 股价飙升37.2%至14.54港元，创1月11日以来新高** 股价将创4月15日以来最大单日涨幅** 中国生物技术公司与礼来 签订协议 (link)，加快用于治疗肥胖症的LAE102的全球临床开发。** 根据协议，礼来将资助并实施LAE102在美国的I期研究，而Laekna将保留该药物的全球权利** 香港医疗保健指数 上涨 2.8%，恒生指数 下跌 0.1** 该股今年以来的跌幅缩小至32.3","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","SG9999015952.SGD","IE0004445239.USD","LU0203202063.USD","LU2468319806.SGD","IE00B4R5TH58.HKD","02105","SGXZ57979304.SGD","LU2106854487.HKD","LU1868836914.USD","LU2264538146.SGD","BK4588","GB00BDT5M118.USD","LU0106261372.USD","LU0385154629.USD","LU0882574055.USD","LU2265009873.SGD","LU1868837300.USD","SGXZ31699556.SGD","LU0061475181.USD","SG9999018857.SGD","BK4534","LU0256863902.USD","BK4533","LU1804176565.USD","LU2237443549.SGD","LU2491050071.SGD","SGXZ99366536.SGD","IE00B1BXHZ80.USD","LU0203201768.USD","LU1868837136.USD","LU1868836757.USD","LU2324357040.USD","LU0689472784.USD","LU0823416689.USD","LU1551013342.USD","LU1093756325.SGD","IE00BK4W5L77.USD","LU0096364046.USD","LU0471298694.HKD","LU0471298777.SGD","LU1988902786.USD","LU0238689110.USD","SG9999014906.USD","LLY","IE00BFTCPJ56.SGD","LU0109391861.USD","LU1868836591.USD","LU0820561818.USD","SG9999015978.USD"],"gpt_icon":0},{"id":"2484153140","title":"来凯医药与礼来合作在美国开展LAE102治疗肥胖症的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2484153140","media":"金吾财讯","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484153140?lang=zh_cn&edition=full","pubTime":"2024-11-20 13:34","pubTimestamp":1732080858,"startTime":"0","endTime":"0","summary":"金吾财讯 | 来凯医药(02105)午后短线拉升，截至发稿，涨24.15，报13.16港元，成交额2.88亿港元。消息面上，公司午间公告，集团已与礼来（NYSE：LLY）签订一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。礼来将负责在美国执行一项I期研究并承担相关费用。集团保留LAE102的全球权益。集团致力于将这种精准治疗带给需要新型治疗选择以实现高质量体重控制的超重和肥胖症患者。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/NDQ1MWJhN2NhODAzMzgwYTAyY2UxMDMzODA5NjE3NDc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NDQ1MWJhN2NhODAzMzgwYTAyY2UxMDMzODA5NjE3NDc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"07e0b9a8029060879506d5b591f8f763","isJumpTheme":false,"source_url":"1948079","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"来凯医药与礼来合作在美国开展LAE102治疗肥胖症的临床试验","news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161","BK4516","LLY"],"gpt_icon":0},{"id":"2484166153","title":"来凯医药与礼来签署LAE102临床合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2484166153","media":"财中社","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484166153?lang=zh_cn&edition=full","pubTime":"2024-11-20 13:27","pubTimestamp":1732080459,"startTime":"0","endTime":"0","summary":"财中社11月20日电来凯医药-B（02105）发布自愿公告，宣布与礼来公司签订了一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。根据协议，礼来将负责在美国执行一项I期研究并承担相关费用，而公司则保留LAE102的全球权利。LAE102是一种自主研发的单克隆抗体，针对在肌肉再生和脂肪代谢中发挥重要作用的ActRIIA受体。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"07e0b9a8029060879506d5b591f8f763","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411203245418615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999014898.SGD","LU0198837287.USD","LU0820561909.HKD","IE00B1BXHZ80.USD","LU0061475181.USD","LU1712237335.SGD","LU0320765059.SGD","LU2491050154.USD","SGXZ31699556.SGD","02105","IE00B2B36J28.USD","LU1366192091.USD","LU2237443382.USD","LU0097036916.USD","LU1093756168.USD","LU1057294990.SGD","LU0689472784.USD","LU1623119135.USD","LU0471298777.SGD","LU0114720955.EUR","LU0820561818.USD","LU1804176565.USD","SGXZ51526630.SGD","LU2237443978.SGD","LU1868836757.USD","LU0079474960.USD","LU2602419157.SGD","SG9999001176.SGD","LU2324357040.USD","LU0094547139.USD","LU0385154629.USD","BK4516","LU0006306889.USD","LU0256863811.USD","BK4585","LU0354030438.USD","LU0058720904.USD","LU0417517546.SGD","LU0640476718.USD","SG9999015978.USD","LU1988902786.USD","LU0354030511.USD","LU0256863902.USD","LU2265009873.SGD","SGXZ81514606.USD","LU2491050071.SGD","LU1280957306.USD","LLY","LU1868837136.USD","LU1974910355.USD"],"gpt_icon":0},{"id":"2484302137","title":"来凯医药-B(02105)与礼来签订一项临床合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2484302137","media":"智通财经","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484302137?lang=zh_cn&edition=full","pubTime":"2024-11-20 12:17","pubTimestamp":1732076241,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B 发布公告， 集团已与礼来公司(礼来)签订一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。礼来将负责在美国执行一项I期研究并承担相关费用。集团保留LAE102的全球权益。据悉，LAE102是自主研发针对Act RIIA的单克隆抗体，Act RIIA是在肌肉再生和脂肪代谢中发挥重要作用的受体。LAE102与GLP -1受体激动剂联用可进一步减少脂肪并显著降低GLP -1受体激动剂导致的肌肉流失，使LAE102成为一种高质量体重控制候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"07e0b9a8029060879506d5b591f8f763","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0256863902.USD","LU0456855351.SGD","LU1551013342.USD","IE00BJLML261.HKD","LU1623119135.USD","IE0004445239.USD","LU1868837300.USD","LU1868836591.USD","SG9999017495.SGD","LU0943347566.SGD","IE00BFTCPJ56.SGD","LU2491049909.HKD","SG9999014914.USD","LU2106854487.HKD","SG9999014880.SGD","LLY","LU1814569148.SGD","LU0466842654.USD","LU0058720904.USD","LU0471298777.SGD","LU0820561909.HKD","LU2360106947.USD","SGXZ51526630.SGD","SG9999001176.USD","LU0097036916.USD","LU1551013425.SGD","LU1983299246.USD","LU2324357040.USD","LU1868836914.USD","LU2237443382.USD","LU2089984988.USD","SG9999015945.SGD","LU1267930730.SGD","LU0354030511.USD","LU1917777945.USD","LU1712237335.SGD","LU0417517546.SGD","LU0882574139.USD","IE0009355771.USD","LU1061106388.HKD","IE00BJJMRZ35.SGD","LU1093756325.SGD","SG9999018857.SGD","LU2063271972.USD","IE00B1BXHZ80.USD","LU2361044949.HKD","GB00BDT5M118.USD","LU0109391861.USD","BK4007"],"gpt_icon":0},{"id":"2484942750","title":"背景资料-诺和诺德减肥药 Wegovy 的价格和供应情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2484942750","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484942750?lang=zh_cn&edition=full","pubTime":"2024-11-19 22:02","pubTimestamp":1732024974,"startTime":"0","endTime":"0","summary":"丹麦 2023 年初，Wegovy 的所有剂量在丹麦上市。Groupe Mutuel 表示，该公司为参加其高级保险计划的成人和青少年承保 Wegovy。日本 2024 年 2 月 22 日，诺和诺德在其首个亚洲国家 推出了 Wegovy， ，大多数患者支付 30% 的医疗费用，与其他药物的报销比例一致。西班牙 诺和诺德于2024 年5 月 1 日在西班牙推出 Wegovy。诺和诺德公司表示，该药物将不享受药品福利计划的补贴。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nL4S3MQ187:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2491049909.HKD","IE00B2B36J28.USD","BK4585","LU2602419157.SGD","IE00B1BXHZ80.USD","LU0109391861.USD","LU1064131342.USD","SGXZ57979304.SGD","LU0289739699.SGD","SG9999014880.SGD","SG9999018857.SGD","LU1868836914.USD","LU0882574139.USD","LU1868837300.USD","LU2491050071.SGD","SG9999018865.SGD","IE00BK4W5L77.USD","LU1814569148.SGD","LLY","LU0122379950.USD","LU0456855351.SGD","LU1551013425.SGD","LU1267930730.SGD","LU2089984988.USD","LU0061475181.USD","GB00BDT5M118.USD","LU2265009873.SGD","IE00B4R5TH58.HKD","LU2237443382.USD","LU1623119135.USD","LU0689472784.USD","LU2237443895.HKD","LU0114720955.EUR","LU1093756168.USD","IE0004445239.USD","LU0672654240.SGD","LU1035775433.USD","LU1069344957.HKD","SG9999001176.USD","IE00BJJMRZ35.SGD","BK4581","LU0096364046.USD","LU0820561818.USD","LU1551013342.USD","SG9999014906.USD","LU0882574055.USD","LU2023250504.SGD","LU0079474960.USD","LU0097036916.USD","BK4534"],"gpt_icon":1},{"id":"2484919941","title":"部分药品企业拒不接受价格整改要求，涉赛诺菲、礼来、恒瑞、正大天晴等","url":"https://stock-news.laohu8.com/highlight/detail?id=2484919941","media":"财经网","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484919941?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:47","pubTimestamp":1732013236,"startTime":"0","endTime":"0","summary":"近日，山西省药械集中竞价采购网发布关于广东联盟阿莫西林等药品集采价格进行调整处置的通知。当中提到，广东省对阿莫西林等药品集中带量采购批次中属于国家组织集采协议期满接续药品进行了价格约谈整改。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119184824abcef8dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119184824abcef8dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0471298694.HKD","IE00BK4W5M84.HKD","LU0256863811.USD","LU0385154629.USD","IE00BFTCPJ56.SGD","LU0198837287.USD","LU0708995401.HKD","IE0004445239.USD","IE00B1BXHZ80.USD","LU0471298777.SGD","LU1551013425.SGD","BK4007","IE0002141913.USD","LU0106261372.USD","LU2063271972.USD","LU2237443978.SGD","SG9999015986.USD","LU0820561909.HKD","SG9999014880.SGD","LLY","LU1093756168.USD","SG9999014906.USD","LU2461242641.AUD","LU2491050071.SGD","LU0096364046.USD","LU0354030438.USD","SGXZ81514606.USD","LU1917777945.USD","SGXZ31699556.SGD","GB00BDT5M118.USD","IE00BK4W5L77.USD","SGXZ99366536.SGD","LU2491049909.HKD","BK4581","LU1983299246.USD","LU1023059063.AUD","LU0122379950.USD","SG9999015952.SGD","LU1551013342.USD","BK4516","LU0456855351.SGD","LU0058720904.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU1712237335.SGD","SG9999014898.SGD","600276","LU1093756325.SGD","LU2023250504.SGD","LU2602419157.SGD","LU0109391861.USD"],"gpt_icon":1},{"id":"2484918479","title":"礼来替尔泊肽SURMOUNT-1研究公布详细结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2484918479","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484918479?lang=zh_cn&edition=full","pubTime":"2024-11-19 17:36","pubTimestamp":1732008961,"startTime":"0","endTime":"0","summary":"11月19日，礼来官微宣布了3期SURMOUNT-1研究（176周治疗期）的详细结果。礼来表示，这是迄今为止完成时间最长的替尔泊肽研究。与安慰剂相比，在176周内每周注射替尔泊肽（5mg，10mg，15mg）可显著降低糖尿病前期的肥胖或超重成人患者发展为2型糖尿病的风险。有效性估计目标显示，三年治疗期间替尔泊肽（15mg剂量）持续减轻患者体重，患者平均体重下降22.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411193244343616.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411193244343616.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1551013342.USD","IE00B1BXHZ80.USD","LU2237443465.HKD","SG9999001176.SGD","LU0198837287.USD","IE00BK4W5M84.HKD","LU0640476718.USD","LU2237438978.USD","LU1868837136.USD","LU0417517546.SGD","LU0672654240.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU1974910355.USD","LU0109391861.USD","LU2106854487.HKD","LU0689472784.USD","SG9999015978.USD","LU0708995401.HKD","LU1057294990.SGD","LU1069344957.HKD","LU2361045086.USD","LU0385154629.USD","LU1280957306.USD","LU1814569148.SGD","LU0882574055.USD","LU2112291526.USD","LU2361044949.HKD","SGXZ81514606.USD","IE00BJT1NW94.SGD","LU1061106388.HKD","BK4007","LLY","LU0238689110.USD","LU1064131342.USD","LU0058720904.USD","LU0006306889.USD","LU0943347566.SGD","LU1551013425.SGD","LU2237443622.USD","SG9999017495.SGD","LU0354030438.USD","LU2089984988.USD","SG9999014898.SGD","SGXZ99366536.SGD","LU1623119135.USD","SG9999014906.USD","LU1804176565.USD","GB00BDT5M118.USD","LU2237443549.SGD"],"gpt_icon":0},{"id":"2484994828","title":"礼来(LLY.US)潜在首创口服小分子显著降低心血管事件高风险成人Lp(a)水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2484994828","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484994828?lang=zh_cn&edition=full","pubTime":"2024-11-19 16:43","pubTimestamp":1732005792,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月18日，礼来宣布每日口服一次脂蛋白[Lp]选择性抑制剂muvalaplin 的一项II期研究结果。研究表明，muvalaplin能显著降低成人体内升高的Lp水平，达到了主要终点。在为期12周的研究中，与安慰剂相比，muvalaplin能明显降低Lp水平。使用完整Lp测定法，安慰剂调整后的降低率高达85.8%，使用apo测定法，降低率高达70.0%。在美国，约有 20% 的人，即大约 6300 万人，Lp水平较高。Lp水平升高可使心脏病发作的风险增加一倍甚至两倍，并与其他心血管问题相关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0203202063.USD","LU0943347566.SGD","LU2112291526.USD","LU0097036916.USD","SG9999017495.SGD","LU1868836757.USD","LU0106261372.USD","LU1868837136.USD","SG9999015945.SGD","LU0122379950.USD","LU1057294990.SGD","LU0114720955.EUR","LU1093756325.SGD","LU2237438978.USD","LU0689472784.USD","LU2237443549.SGD","SG9999001176.USD","LU0471298694.HKD","LU0203201768.USD","LU1623119135.USD","LU0820561909.HKD","LU0256863902.USD","LU0061475181.USD","LU0058720904.USD","LU0882574139.USD","GB00BDT5M118.USD","BK4534","LU2237443622.USD","LU1064131342.USD","LU2602419157.SGD","LU1127390331.HKD","SGXZ57979304.SGD","LU0256863811.USD","IE00B2B36J28.USD","LU1267930730.SGD","LU1983299246.USD","SGXZ31699556.SGD","LU0289739699.SGD","LU2106854487.HKD","LU2491050154.USD","LU0640476718.USD","LU0672654240.SGD","LU2237443465.HKD","SG9999014914.USD","BK4007","LU0466842654.USD","LU2237443382.USD","LU2361044949.HKD","LU0354030511.USD","LLY"],"gpt_icon":1},{"id":"2484986599","title":"阿斯利康、礼来亚洲基金等入股呈元科技","url":"https://stock-news.laohu8.com/highlight/detail?id=2484986599","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484986599?lang=zh_cn&edition=full","pubTime":"2024-11-19 15:23","pubTimestamp":1732001003,"startTime":"0","endTime":"0","summary":"天眼查App显示，11月15日，呈元（广州）科技有限公司发生工商变更，新增阿斯利康旗下无锡阿斯利康中金壹号创业投资合伙企业、礼来亚洲基金旗下苏州礼润股权投资中心、淄博芯能天吉股权投资合伙企业等为股东，同时注册资本由约176.3万人民币增至约235.7万人民币。据悉，呈元科技为AI+合成肽新药研发企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119152323abce808a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119152323abce808a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4534","LU1868836757.USD","LU1712237335.SGD","LU2456880835.USD","LU0385154629.USD","LU0708995401.HKD","LU2491050071.SGD","SGXZ57979304.SGD","SG9999013999.USD","LU0823416689.USD","LU1127390331.HKD","LU1868837300.USD","LU0203202063.USD","LU2324357040.USD","LU2462157665.USD","LU2089984988.USD","SGXZ31699556.SGD","IE00BK4W5L77.USD","LU2237443622.USD","SGXZ81514606.USD","LU0256863902.USD","LU0006306889.USD","LU1551013342.USD","LLY","LU0354030511.USD","LU0471298777.SGD","LU1868837136.USD","LU2023250504.SGD","LU2112291526.USD","SG9999017495.SGD","AZN","LU1814569148.SGD","LU1267930730.SGD","LU0640476718.USD","LU0198837287.USD","LU0109394709.USD","LU1974910355.USD","LU1061106388.HKD","BK4585","LU1917777945.USD","BK4007","LU2602419157.SGD","IE00B1BXHZ80.USD","LU0122379950.USD","GB00BDT5M118.USD","LU0238689110.USD","SG9999015945.SGD","LU2468319806.SGD","LU1023059063.AUD","BK4581"],"gpt_icon":0},{"id":"2484598810","title":"研究发现礼来药片可将遗传性胆固醇降低近 86","url":"https://stock-news.laohu8.com/highlight/detail?id=2484598810","media":"Reuters","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484598810?lang=zh_cn&edition=full","pubTime":"2024-11-19 03:52","pubTimestamp":1731959527,"startTime":"0","endTime":"0","summary":"研究人员在芝加哥举行的美国心脏协会会议上报告说，这种名为muvalaplin的药物通过传统的血液测试使脂蛋白 或 Lp 的水平降低了70%，而通过该公司开发的一种更特殊的测试方法则降低了近86%。每16周或24周注射一次300毫克或450毫克的zerlasiran，可在36至60周的随访期间将脂蛋白，降低80%至85%，且无重大安全问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","SG9999014880.SGD","SG9999017495.SGD","SGXZ51526630.SGD","LU0466842654.USD","IE00BJJMRZ35.SGD","LU0640476718.USD","LU1814569148.SGD","LU2106854487.HKD","LU1023059063.AUD","LU0354030511.USD","LU1868836914.USD","LU0417517546.SGD","LU2237443382.USD","LU0198837287.USD","LU2237443895.HKD","IE0009355771.USD","IE00BJLML261.HKD","LU1093756168.USD","LU2265009873.SGD","LU2468319806.SGD","BK4534","LU0471298777.SGD","LU1035775433.USD","BK4516","LU1868836757.USD","IE00BFTCPJ56.SGD","LU0354030438.USD","LU2237438978.USD","SG9999014914.USD","BK4581","LU1280957306.USD","BK4533","LLY","SG9999001176.SGD","LU2237443549.SGD","LU0256863902.USD","LU0061475181.USD","LU0106261372.USD","LU0882574139.USD","LU0672654240.SGD","LU2089984988.USD","LU1267930730.SGD","LU2237443622.USD","LU2361044949.HKD","IE00B2B36J28.USD","LU0823416689.USD","LU2063271972.USD","SG9999015978.USD","LU1623119135.USD"],"gpt_icon":1},{"id":"2484607758","title":"美股走势-Henry Schein Inc、Palantir Technologies、Uber Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2484607758","media":"路透中文","labels":["event"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484607758?lang=zh_cn&edition=full","pubTime":"2024-11-19 03:12","pubTimestamp":1731957174,"startTime":"0","endTime":"0","summary":".N美国东部时间13:31，道琼斯工业平均指数.DJI下跌0.12%，报43,394.67点。标普500指数.SPX上涨0.42%，报5894.99点；纳斯达克综合指数.IXIC上涨0.62%，报18798.28点。标准普尔 500 指数.PG.INX百分比涨幅前三名是： ** 超级微型计算机公司SMCI.O，上涨 20.2. ** Henry Schein Inc HSIC.O，上涨 6.9 标普500指数.PL.INX跌幅前三名： ** Amentum Holdings Inc AMTM.N，下跌 9.0. 纽约证券交易所.PG.N百分比涨幅前三名： ** Finance of America Companies Inc FOA.N，上涨 21.3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4T3MP1CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNVD.UK","CMAX","MARA","LUV","PPTA","NTLA","LBRT","GL","NVDU","DCOM","WBD","JBLU","DE","NVDS.UK","TSLA","MSTR","DAL","NVD3.UK","NVDY","2NVD.UK","HIMS","LLY","BIIB","TPR","BBWI","ASB","NVD","NEM","NKE","NVDL","NVD2.UK","TWST","MRNA","CVS","HOOD","HSIC","NVDX","AILE","3NVD.UK","NVDA","UAL","AEO","GAP","HPE","BTBT","MBI","GRNT","VSCO","VLY"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.lilly.com","stockEarnings":[{"period":"1week","weight":-0.0719},{"period":"1month","weight":-0.1685},{"period":"3month","weight":-0.2104},{"period":"6month","weight":-0.0669},{"period":"1year","weight":0.2714},{"period":"ytd","weight":0.2925}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":0.0118},{"period":"3month","weight":0.0616},{"period":"6month","weight":0.1153},{"period":"1year","weight":0.3028},{"period":"ytd","weight":0.2423}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"礼来公司于1901年在印第安纳州注册成立，其前身是1876年由伊利·礼来上校在印第安纳州印第安纳波利斯创立的药品生产企业。公司发现，开发，制造和销售重要医药产品。公司的宗旨是将“关爱”与“发现”结合起来，为世界各地的人们创造更美好的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.011498},{"month":2,"riseRate":0.5,"avgChangeRate":-0.002909},{"month":3,"riseRate":0.613636,"avgChangeRate":0.015389},{"month":4,"riseRate":0.555556,"avgChangeRate":0.018718},{"month":5,"riseRate":0.422222,"avgChangeRate":0.014916},{"month":6,"riseRate":0.6,"avgChangeRate":0.02296},{"month":7,"riseRate":0.555556,"avgChangeRate":-0.000346},{"month":8,"riseRate":0.422222,"avgChangeRate":0.004313},{"month":9,"riseRate":0.444444,"avgChangeRate":0.001418},{"month":10,"riseRate":0.577778,"avgChangeRate":0.012708},{"month":11,"riseRate":0.733333,"avgChangeRate":0.025203},{"month":12,"riseRate":0.590909,"avgChangeRate":0.031834}],"exchange":"NYSE","name":"礼来","nameEN":"Eli Lilly"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"礼来,LLY,礼来股票,礼来股票老虎,礼来股票老虎国际,礼来行情,礼来股票行情,礼来股价,礼来股市,礼来股票价格,礼来股票交易,礼来股票购买,礼来股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}